NasdaqCM:FENC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. More Details


Snowflake Analysis

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Fennec Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FENC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.9%

FENC

-2.8%

US Biotechs

-5.3%

US Market


1 Year Return

40.2%

FENC

22.7%

US Biotechs

10.4%

US Market

Return vs Industry: FENC exceeded the US Biotechs industry which returned 25% over the past year.

Return vs Market: FENC exceeded the US Market which returned 12% over the past year.


Shareholder returns

FENCIndustryMarket
7 Day-1.9%-2.8%-5.3%
30 Day21.0%-2.6%-2.1%
90 Day-10.5%-2.5%1.7%
1 Year40.2%40.2%24.9%22.7%12.9%10.4%
3 Year-20.9%-20.9%14.3%8.6%34.3%25.4%
5 Year480.4%480.4%5.7%-2.0%73.7%54.3%

Price Volatility Vs. Market

How volatile is Fennec Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fennec Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

5.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FENC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FENC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FENC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: FENC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FENC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FENC is overvalued based on its PB Ratio (5.3x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Fennec Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

54.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FENC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: FENC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FENC's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if FENC's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if FENC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FENC's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Fennec Pharmaceuticals performed over the past 5 years?

-48.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FENC is currently unprofitable.

Growing Profit Margin: FENC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FENC is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.

Accelerating Growth: Unable to compare FENC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FENC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).


Return on Equity

High ROE: FENC has a negative Return on Equity (-39%), as it is currently unprofitable.


Next Steps

Financial Health

How is Fennec Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: FENC's short term assets ($38.9M) exceed its short term liabilities ($3.2M).

Long Term Liabilities: FENC has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: FENC is debt free.

Reducing Debt: FENC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FENC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: FENC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.7% each year


Next Steps

Dividend

What is Fennec Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FENC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FENC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FENC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FENC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FENC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Rosty Raykov (44 yo)

11.25yrs

Tenure

US$1,477,136

Compensation

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc) since July 2009 and serves as its President. Mr. Ray ...


CEO Compensation Analysis

Compensation vs Market: Rosty's total compensation ($USD1.48M) is about average for companies of similar size in the US market ($USD1.36M).

Compensation vs Earnings: Rosty's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Rostislav Raykov
CEO & Director11.25yrsUS$1.48m0.78%
$ 1.5m
Robert Andrade
Chief Financial Officer4.83yrsUS$863.77k0.60%
$ 1.2m
Shubh Goel
Chief Commercial Officer1yrUS$1.23m0%
$ 0
Mark Gowland
Controller4.83yrsno datano data
Lei Fang
President of Pharstat Incno datano datano data
Anne McKay
Regulatory Consultant10.42yrsno datano data
Alexander Smith
Consultantno datano datano data

4.8yrs

Average Tenure

45.5yo

Average Age

Experienced Management: FENC's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rostislav Raykov
CEO & Director11.25yrsUS$1.48m0.78%
$ 1.5m
Chris Rallis
Independent Director9.17yrsUS$126.65k0%
$ 0
Khalid Islam
Independent Chairman of the Board4.83yrsUS$190.19k0%
$ 0
Jodi Cook
Independent Director1yrUS$112.43k0%
$ 0
Adrian Haigh
Independent Director6.42yrsUS$124.15k0%
$ 0
Marco Brughera
Independent Director4.17yrsUS$124.15k0%
$ 0

5.6yrs

Average Tenure

63yo

Average Age

Experienced Board: FENC's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: FENC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.4%.


Top Shareholders

Company Information

Fennec Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fennec Pharmaceuticals Inc.
  • Ticker: FENC
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$191.692m
  • Shares outstanding: 25.36m
  • Website: https://www.fennecpharma.com

Number of Employees


Location

  • Fennec Pharmaceuticals Inc.
  • 68 TW Alexander Drive
  • PO Box 13628
  • Research Triangle Park
  • North Carolina
  • 27709
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FRXTSX (The Toronto Stock Exchange)YesCommon SharesCACADJun 2001
RV41DB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2001
FENCNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJun 2001

Biography

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/31 00:05
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.